Details for Patent: 8,173,708
✉ Email this page to a colleague
Which drugs does patent 8,173,708 protect, and when does it expire?
Patent 8,173,708 protects NAMZARIC and is included in one NDA.
Protection for NAMZARIC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-seven patent family members in eighteen countries.
Summary for Patent: 8,173,708
Title: | Method and composition for administering an NMDA receptor antagonist to a subject |
Abstract: | The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. |
Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV) |
Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
Application Number: | 12/757,819 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,173,708 |
Patent Claim Types: see list of patent claims | Use; Dosage form; Formulation; |
Recent additions to Drugs Protected by US Patent 8,173,708
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 8,173,708
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-002 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,173,708
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E481096 | ⤷ Try a Trial | |||
Australia | 2005209310 | ⤷ Try a Trial | |||
Australia | 2005215767 | ⤷ Try a Trial | |||
Australia | 2005215775 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |